Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJAVN7)

Drug Name

GSK3186899 Drug Info

Synonyms

CHEMBL4563818; 1972617-87-0; 3,3,3-Trifluoro-N-(trans-4-((3-((S)-2-methylmorpholino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)cyclohexyl)propane-1-sulfonamide; SCHEMBL17948393; SCHEMBL20878264; SCHEMBL20878281; BDBM50517287; TQ0152; DDD-853651; SB18814; HY-112622; CS-0058580; 3,3,3-trifluoro-N-((1S,4r)-4-((3-((S)-2-methylmorpholino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)cyclohexyl)propane-1-sulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Leishmaniasis	1F54	Phase 1	[1]

Cross-matching ID

PubChem CID: 122429808
TTD Drug ID: DMJAVN7

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cyclin-dependent kinase 12 (CDK12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
THZ531	DMBZ2MF	Solid tumour/cancer	2A00-2F9Z	Investigative	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cyclin-dependent kinase 12 (CDK12)	TTJ21A9	CDK12_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03874234) Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of GlaxoSmithKline.
3	Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016 Oct;12(10):876-84.